GHRP-6
Overview
A synthetic hexapeptide growth hormone secretagogue that stimulates the anterior pituitary via GHS-R1a receptor activation. GHRP-6 produces significant GH release and also potently stimulates appetite through ghrelin-mimetic activity in hypothalamic feeding centers. It increases gastric motility and has cytoprotective effects on gastric and cardiac tissue through NO-mediated pathways.
Key Research Findings
Robust GH-releasing activity confirmed in multiple clinical studies with dose-dependent responses. Notable appetite-stimulating effect limits its use in weight management contexts. Research in Cuba demonstrated cardioprotective and gastroprotective effects. Synergistic with CJC-1295 and other GHRH analogs for enhanced GH pulsatility.
Subcutaneous injection, Intravenous
Investigational
Interested in GHRP-6?
Find a verified provider experienced with GHRP-6 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a GHRP-6 ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.